• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Integra LifeSciences Holdings Corporation (Amendment)

    2/14/23 2:31:52 PM ET
    $IART
    Medical/Dental Instruments
    Health Care
    Get the next $IART alert in real time by email
    SC 13G/A 1 d430695dsc13ga.htm SC 13G/A SC 13G/A

     

     

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    Schedule 13G

    Under the Securities Exchange Act of 1934

    (Amendment No. 20)*

     

     

    Integra LifeSciences Holdings Corporation

    (Name of Issuer)

    Common stock, $.01 par value

    (Title of Class of Securities)

    457985208

    (CUSIP Number)

    December 31, 2022

    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☐ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☒ Rule 13d-1(d)

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


    CUSIP No. 457985208    SCHEDULE 13G    Page 2 of 9

     

      1    

      NAMES OF REPORTING PERSON: Tru St Partnership LP

      I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (entities only):

     

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)

      (a)  ☒        (b)  ☐

     

      3  

      SEC USE ONLY

     

      4  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      Pennsylvania

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH:

       5    

      SOLE VOTING POWER

     

      0 shares

       6  

      SHARED VOTING POWER

     

      8,515,930 shares

       7  

      SOLE DISPOSITIVE POWER

     

      0 shares

       8  

      SHARED DISPOSITIVE POWER

     

      8,515,930 shares

      9    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      8,515,930 shares

    10  

      CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (See Instructions)

     

      ☐

    11  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

      10.20%

    12  

      TYPE OF REPORTING PERSON (See Instructions)

     

      PN


    CUSIP No. 457985208    SCHEDULE 13G    Page 3 of 9

     

      1    

      NAMES OF REPORTING PERSON: Provco, LLC

      I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (entities only):

     

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)

      (a)  ☒        (b)  ☐

     

      3  

      SEC USE ONLY

     

      4  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      Delaware

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH:

       5    

      SOLE VOTING POWER

     

      0 shares

       6  

      SHARED VOTING POWER

     

      8,515,930 shares

       7  

      SOLE DISPOSITIVE POWER

     

      0 shares

       8  

      SHARED DISPOSITIVE POWER

     

      8,515,930 shares

      9    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      8,515,930 shares

    10  

      CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (See Instructions)

     

      ☐

    11  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

      10.20%

    12  

      TYPE OF REPORTING PERSON (See Instructions)

     

      OO


    CUSIP No. 457985208    SCHEDULE 13G    Page 4 of 9

     

    ITEM 1.    (a)    Name of Issuer: Integra LifeSciences Holdings Corporation
       (b)    Address of Issuer’s Principal Executive Offices: 1100 Campus Road, Princeton, NJ 08540
    ITEM 2.    (a)    Name of Person Filing: See (c) below
       (b)    Address or Principal Business Office: See (c) below
       (c)   

    Citizenship of each Reporting Person is:

     

    Tru St Partnership LP

    795 East Lancaster Avenue, Suite 200

    Villanova, Pennsylvania 19085

    Pennsylvania limited partnership

     

    AS of December 31, 2022, Provco Leasing Corporation was the corporate general partner of Tru St Partnership LP:

     

    Provco Leasing Corporation

    1100 North Market Street, 4th Floor

    Wilmington, Delaware 19890

    Delaware corporation

     

    As of January 1, 2023, Provco, LLC became the general partner of Tru St Partnership LP:

     

    Provco, LLC

    1100 North Market Street, 4th Floor

    Wilmington, Delaware 19890

    Delaware limited liability company

       (d)    Title of Class of Securities: common stock, $0.01 par value
       (e)    CUSIP Number: 457985208
    ITEM 3.       Not applicable.
    ITEM 4.       Ownership: Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.
       (a)    Amount beneficially owned: As of December 31, 2022, Tru St Partnership LP (“Tru St”) may be deemed the beneficial owner of 8,515,930 shares of common stock. Provco Leasing Corporation (“Provco Leasing”) was the corporate general partner of Tru St as of December 31, 2022. Provco, LLC (“Provco”) became the general partner of Tru St as of January 1, 2023. Provco Leasing was, as of December 31, 2022, the beneficial owner of 0 shares of common stock.
       (b)    Percent of Class: Based on 83,518,163 shares of the Issuer’s common stock outstanding as of October 24, 2022 as reported in the Issuer’s Form 10-Q for the quarter ended September 30, 2022: Tru St may be deemed the beneficial owner of 10.20% of the Issuer’s common stock; and Provco Leasing may be deemed the beneficial owner of 10.20% of the Issuer’s common stock as of December 31, 2022.


    CUSIP No. 457985208    SCHEDULE 13G    Page 5 of 9

     

       (c)    The Reporting Persons have the power to vote or dispose of the number of shares as follows:
         

    (i) Sole power to vote or direct the vote. Tru St may be deemed to have sole power to vote or direct the vote of 0 shares of common stock. Provco Leasing may be deemed to have sole power to vote or direct the vote of 0 shares of common stock.

         

    (ii)  Shared power to vote or direct the vote. As of December 31, 2022, Tru St and Provco Leasing may be deemed to share the power to vote or direct the vote with respect to 8,515,930 shares of common stock.

         

    (iii)  Sole power to dispose or direct the disposition. Tru St has sole power to dispose or control the disposition of 0 shares of common stock. Provco Leasing has sole power to dispose or control the disposition of 0 shares of common stock.

         

    (iv) Shared power to dispose or direct the disposition. As of December 31, 2022, Tru St and Provco Leasing may be deemed to have shared power to dispose of or shared power to direct the disposition of 8,515,930 shares of common stock.

    ITEM 5.    Ownership of Five Percent or Less of a Class
       Not applicable.
    ITEM 6.    Ownership of More than Five Percent on Behalf of Another Person
       Not applicable.
    ITEM 7.    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company
       Not applicable.
    ITEM 8.    Identification and Classification of Members of the Group
       Exhibit A attached hereto identifies each member of the group filing this Schedule 13G/A pursuant to Rule 13d-1(d).
    ITEM 9.    Notice of Dissolution of Group
       Not applicable.
    ITEM 10.    Certification
       Not applicable.


    CUSIP No. 457985208    SCHEDULE 13G    Page 6 of 9

     

    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Date: February 14, 2023

     

    TRU ST PARTNERSHIP LP
    By:   /s/ Gary Dilella
    Name:   Gary DiLella
    Its:   Vice President
    PROVCO, LLC
    By:   /s/ Gary Dilella
    Name:   Gary DiLella
    Its:   Vice President


    CUSIP No. 457985208    SCHEDULE 13G    Page 7 of 9

     

    Exhibit Index

     

    Exhibit

     

    Title

       Page No.  

    Exhibit A

      Group Members      8  

    Exhibit B

      Joint Filing Agreement      9  
    Get the next $IART alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $IART

    DatePrice TargetRatingAnalyst
    3/31/2025Hold → Buy
    Argus
    12/2/2024$25.00 → $20.00Underweight
    Morgan Stanley
    10/7/2024Sell → Neutral
    BTIG Research
    7/30/2024$22.00Neutral → Sell
    BTIG Research
    7/30/2024$30.00 → $23.00Neutral → Sell
    Citigroup
    5/7/2024Outperform → Perform
    Oppenheimer
    5/7/2024$45.00 → $25.00Overweight → Equal Weight
    Wells Fargo
    4/3/2024$38.00Sell → Neutral
    Citigroup
    More analyst ratings

    $IART
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Integra upgraded by Argus

    Argus upgraded Integra from Hold to Buy

    3/31/25 8:28:08 AM ET
    $IART
    Medical/Dental Instruments
    Health Care

    Morgan Stanley initiated coverage on Integra with a new price target

    Morgan Stanley initiated coverage of Integra with a rating of Underweight and set a new price target of $20.00 from $25.00 previously

    12/2/24 8:17:21 AM ET
    $IART
    Medical/Dental Instruments
    Health Care

    Integra upgraded by BTIG Research

    BTIG Research upgraded Integra from Sell to Neutral

    10/7/24 7:56:40 AM ET
    $IART
    Medical/Dental Instruments
    Health Care

    $IART
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Essig Stuart disposed of $2,724,000 worth of shares (200,000 units at $13.62) and acquired $2,724,000 worth of shares (200,000 units at $13.62), decreasing direct ownership by 15% to 1,152,236 units (SEC Form 4)

    4 - INTEGRA LIFESCIENCES HOLDINGS CORP (0000917520) (Issuer)

    8/18/25 4:43:39 PM ET
    $IART
    Medical/Dental Instruments
    Health Care

    EVP & Chief Financial Officer Knight Lea Daniels covered exercise/tax liability with 2,561 shares, decreasing direct ownership by 4% to 58,578 units (SEC Form 4)

    4 - INTEGRA LIFESCIENCES HOLDINGS CORP (0000917520) (Issuer)

    7/7/25 5:06:50 PM ET
    $IART
    Medical/Dental Instruments
    Health Care

    SVP, Fin & Princ Acct Officer Mosebrook Jeffrey covered exercise/tax liability with 3,345 shares, decreasing direct ownership by 8% to 36,600 units (SEC Form 4)

    4 - INTEGRA LIFESCIENCES HOLDINGS CORP (0000917520) (Issuer)

    7/7/25 5:06:02 PM ET
    $IART
    Medical/Dental Instruments
    Health Care

    $IART
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Essig Stuart bought $1,499,979 worth of shares (52,641 units at $28.49), increasing direct ownership by 12% to 487,922 units (SEC Form 4)

    4 - INTEGRA LIFESCIENCES HOLDINGS CORP (0000917520) (Issuer)

    5/24/24 4:08:19 PM ET
    $IART
    Medical/Dental Instruments
    Health Care

    Hill Barbara B bought $995,816 worth of shares (36,350 units at $27.40) (SEC Form 4)

    4 - INTEGRA LIFESCIENCES HOLDINGS CORP (0000917520) (Issuer)

    5/22/24 4:09:18 PM ET
    $IART
    Medical/Dental Instruments
    Health Care

    $IART
    SEC Filings

    View All

    $IART
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Integra LifeSciences Holdings Corporation

    SCHEDULE 13G/A - INTEGRA LIFESCIENCES HOLDINGS CORP (0000917520) (Subject)

    8/5/25 11:50:40 AM ET
    $IART
    Medical/Dental Instruments
    Health Care

    SEC Form S-8 filed by Integra LifeSciences Holdings Corporation

    S-8 - INTEGRA LIFESCIENCES HOLDINGS CORP (0000917520) (Filer)

    7/31/25 4:51:57 PM ET
    $IART
    Medical/Dental Instruments
    Health Care

    SEC Form 10-Q filed by Integra LifeSciences Holdings Corporation

    10-Q - INTEGRA LIFESCIENCES HOLDINGS CORP (0000917520) (Filer)

    7/31/25 4:02:56 PM ET
    $IART
    Medical/Dental Instruments
    Health Care

    REPAY Appoints New Chief Financial Officer

    Repay Holdings Corporation (NASDAQ:RPAY) ("REPAY" or the "Company"), a leading provider of integrated payment processing solutions, today announced the appointment of Robert Houser as Chief Financial Officer of the Company, effective September 8, 2025. "We are extremely excited to welcome Rob to REPAY. Rob brings over a decade of divisional CFO and operational experience within the payment industry to help him contribute immediately. Rob has held key strategic roles across his career and will be a great partner in running our company," said John Morris, Co-Founder and CEO. Most recently, Rob served as the Group CFO of the Public Sector and Advisor at Conduent Incorporated (NASDAQ:CNDT)

    8/11/25 4:06:00 PM ET
    $CNDT
    $FI
    $IART
    Real Estate
    Medical/Dental Instruments
    Health Care
    Biotechnology: Pharmaceutical Preparations

    Integra LifeSciences Reports Second Quarter 2025 Financial Results

    PRINCETON, N.J., July 31, 2025 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ:IART), a leading global medical technology company, today reported financial results for the second quarter ending June 30, 2025. Second Quarter 2025 Highlights Second quarter revenues exceeded guidance; adjusted earnings per diluted share (EPS) at the top end of the rangeSecond quarter revenues of $415.6 million decreased (0.6)% on a reported basis and (1.4)% on an organic basis compared to the prior year.Second quarter GAAP earnings per diluted share of $(6.31), compared to $(0.16) in the prior year primarily reflecting a goodwill impairment charge of $511 million, recorded during t

    7/31/25 6:00:00 AM ET
    $IART
    Medical/Dental Instruments
    Health Care

    Integra LifeSciences to Host Second Quarter 2025 Financial Results Conference Call on July 31, 2025

    PRINCETON, N.J., July 14, 2025 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ:IART), a leading global medical technology company, will release second quarter 2025 financial results on Thursday, July 31, 2025, prior to the market open. In conjunction with the earnings release, Integra's management team will host a conference call at 8:30 a.m. ET. A live webcast will be available on the Investors section of the Company's website at investor.integralife.com. For those planning to participate on the call, register here to receive dial-in details and an individual pin. While not required, joining 10 minutes before the event starts is recommended. A webcast replay of the

    7/14/25 4:35:00 PM ET
    $IART
    Medical/Dental Instruments
    Health Care

    $IART
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Integra LifeSciences Holdings Corporation

    SC 13G - INTEGRA LIFESCIENCES HOLDINGS CORP (0000917520) (Subject)

    11/12/24 5:20:30 PM ET
    $IART
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Integra LifeSciences Holdings Corporation

    SC 13G/A - INTEGRA LIFESCIENCES HOLDINGS CORP (0000917520) (Subject)

    11/12/24 12:54:20 PM ET
    $IART
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Integra LifeSciences Holdings Corporation

    SC 13G/A - INTEGRA LIFESCIENCES HOLDINGS CORP (0000917520) (Subject)

    8/12/24 10:06:35 AM ET
    $IART
    Medical/Dental Instruments
    Health Care

    $IART
    Financials

    Live finance-specific insights

    View All

    Integra LifeSciences Reports Second Quarter 2025 Financial Results

    PRINCETON, N.J., July 31, 2025 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ:IART), a leading global medical technology company, today reported financial results for the second quarter ending June 30, 2025. Second Quarter 2025 Highlights Second quarter revenues exceeded guidance; adjusted earnings per diluted share (EPS) at the top end of the rangeSecond quarter revenues of $415.6 million decreased (0.6)% on a reported basis and (1.4)% on an organic basis compared to the prior year.Second quarter GAAP earnings per diluted share of $(6.31), compared to $(0.16) in the prior year primarily reflecting a goodwill impairment charge of $511 million, recorded during t

    7/31/25 6:00:00 AM ET
    $IART
    Medical/Dental Instruments
    Health Care

    Integra LifeSciences to Host Second Quarter 2025 Financial Results Conference Call on July 31, 2025

    PRINCETON, N.J., July 14, 2025 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ:IART), a leading global medical technology company, will release second quarter 2025 financial results on Thursday, July 31, 2025, prior to the market open. In conjunction with the earnings release, Integra's management team will host a conference call at 8:30 a.m. ET. A live webcast will be available on the Investors section of the Company's website at investor.integralife.com. For those planning to participate on the call, register here to receive dial-in details and an individual pin. While not required, joining 10 minutes before the event starts is recommended. A webcast replay of the

    7/14/25 4:35:00 PM ET
    $IART
    Medical/Dental Instruments
    Health Care

    Integra LifeSciences Reports First Quarter 2025 Financial Results

    PRINCETON, N.J., May 05, 2025 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ:IART), a leading global medical technology company, today reported financial results for the first quarter ending March 31, 2025. First Quarter 2025 Highlights First quarter revenues of $382.7 million increased 3.7% on a reported basis and decreased 3.5% on an organic basis compared to the prior year. First quarter GAAP earnings per diluted share of $(0.33), compared to $(0.04) in the prior year; adjusted earnings per diluted share of $0.41, compared to $0.55 in the prior year.Reaffirming full-year 2025 revenue guidance range and updating adjusted EPS guidance to account for the impact

    5/5/25 6:30:00 AM ET
    $IART
    Medical/Dental Instruments
    Health Care

    $IART
    Leadership Updates

    Live Leadership Updates

    View All

    REPAY Appoints New Chief Financial Officer

    Repay Holdings Corporation (NASDAQ:RPAY) ("REPAY" or the "Company"), a leading provider of integrated payment processing solutions, today announced the appointment of Robert Houser as Chief Financial Officer of the Company, effective September 8, 2025. "We are extremely excited to welcome Rob to REPAY. Rob brings over a decade of divisional CFO and operational experience within the payment industry to help him contribute immediately. Rob has held key strategic roles across his career and will be a great partner in running our company," said John Morris, Co-Founder and CEO. Most recently, Rob served as the Group CFO of the Public Sector and Advisor at Conduent Incorporated (NASDAQ:CNDT)

    8/11/25 4:06:00 PM ET
    $CNDT
    $FI
    $IART
    Real Estate
    Medical/Dental Instruments
    Health Care
    Biotechnology: Pharmaceutical Preparations

    Jan De Witte joins GHO Capital as Operating Partner

    Jan De Witte joins GHO Capital as Operating Partner Former CEO of Integra LifeSciences with significant strategic and operational experience to support GHO Capital's portfolio London, UK – 11 February 2025: Global Healthcare Opportunities, or GHO Capital Partners LLP ("GHO"), the European specialist investor in global healthcare, is pleased to announce the appointment of Jan De Witte as Operating Partner. Jan is an accomplished senior executive with extensive experience leading international growth and transformation for global technology and life sciences companies. Prior to joining GHO, he was Chief Executive Officer and member of the Board of Directors at Integra LifeSciences (("Integr

    2/11/25 4:30:00 AM ET
    $IART
    $RMD
    Medical/Dental Instruments
    Health Care

    Integra LifeSciences Announces Appointment of Mojdeh Poul as President and Chief Executive Officer

    PRINCETON, N.J., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ:IART), a leading global medical technology company, today announced that its board of directors has appointed Mojdeh Poul as the new president and chief executive officer, effective January 6, 2025. Ms. Poul will also join the Integra board when she assumes the role. She will succeed Jan De Witte, who will remain president and CEO until January 6, 2025. Stuart Essig will remain executive chairman of Integra for a limited period of time before returning to his prior role as non-executive chairman. "The board and I are thrilled to welcome Mojdeh as Integra's next president and CEO," sa

    11/4/24 6:00:00 AM ET
    $IART
    Medical/Dental Instruments
    Health Care